Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Engines getting lubed up big volume $$ wall 0.53
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1420)
•••
Comment by Pandoraon Nov 02, 2021 9:58am
100 Views
Post# 34076708

RE:Engines getting lubed up big volume $$ wall 0.53

RE:Engines getting lubed up big volume $$ wall 0.53
jopatclo wrote: Nice!! another sale. good to hear..

https://twitter.com/ventripoint/status/1455523340639211520



From what I can tell on what has been posted on here a lot of people think the first unit was not a sale
but a gift. Why do you say "another sale"? And there is no news release this time ---- yet!

Toronto, Ontario – The Newswire – October 21, 2021 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT); (OTC:VPTDF) is pleased to announce that the East Midlands Congenital Heart Centre in Leicester, UK has received the VMS+3.0 unit.

This is the second site in the UK to receive the VMS+3.0 as a tool for aiding in the diagnosis and monitoring of patients with heart disease. Regular monitoring and reassessments are especially critical for the care of patients with congenital heart disease (CHD), as well as for managing case load of new patients. The VMS+ system is a tool for regular monitoring and assessments because it provides a rapid and complete visualization of the function of the whole heart.



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities